Sungening Biotechnology Co., Ltd. is a globally renowned pharmaceutical innovation enterprise that focuses on the research and development of drugs for metabolic diseases, anti-tumor and anti infective fields, starting from drugs that do not meet clinical needs.
Sungening Biotechnology Co., Ltd. is a globally renowned pharmaceutical innovation enterprise that focuses on the research and development of drugs for metabolic diseases, anti-tumor and anti infective fields, starting from drugs that do not meet clinical needs.
Shenzhen Sungening Biological Co., Ltd, shorted as Sungening, established in 2021, has risen rapidly amidst the wave of innovative drug research and development, deploying several innovative drug pipelines in fields such as anti-infective, metabolic diseases, and oncology, with a particular focus on groundbreaking advancements in anti-fungal infections and deep exploration of oral cyclic peptide technology. Our aim is to address the urgent clinical need for anti-fungal treatment options, striving to make oral cyclic peptide drugs the first choice for patients, simplifying treatment processes, reducing psychological burdens, and enhancing patient compliance.
Sungening has achieved notable milestones in the cutting-edge fields of anti-fungal infections and oral cyclic peptides. One of our innovative drug pipelines targeting anti-fungal infections has successfully obtained IND (investigational new drug), marking a substantial step into clinical trials in this field. Two more pipelines are undergoing intense clinical application processes, demonstrating the company's robust R&D execution and project advancement capabilities. Furthermore, two pipelines have progressed to the PCC (Pre-Clinical Candidate) stage, foreshadowing the potential for more innovative breakthroughs to benefit a broader patient population in the future.
Co-founder, Senior Vice President and Chief Scientist Officer (CSO)
Dr. Yuan, Co-founder, Senior Vice President and Chief Scientist officer (CSO) Dr. Chenguang Yuan, an expert in medicinal chemistry, graduated with a bachelor's degree from Xiamen University and a Ph.D. from Colorado State University. He previously served as a principal researcher in the innovative drug development departments at GD Searle and Amgen in the United States, an adjunct professor at the School of Life Sciences at Xiamen University, and a senior vice president at Hyperway Pharmaceuticals. He is a specially-appointed expert in Sichuan Province, a high-level innovative talent under Fujian Province's "Hundred Talents Program," and a leading entrepreneurial talent in Xiamen's "Double Hundred Plan." With over 30 years of experience in innovative drug research, Dr. Yuan specializes in innovative drug development and design, particularly excelling in the field of Class 1.1 small molecule innovative drugs. He has unique and keen insights into organic chemistry and drug synthesis and is the inventor of several innovative drug compounds. Dr. Yuan has published 28 papers in renowned journals both domestically and internationally. He has been awarded 25 compound invention patents in the United States and has applied for over 20 patents in China in recent years.
Co-founder, Senior Vice President and Chief Technology Officer (CTO)
Dr. Yan Chen, Co-founder, Senior Vice President and Chief Technology Officer (CTO) Dr. Chen, a well-known expert in the field of glucose and lipid metabolism research, graduated from the Department of Medicine and Molecular Genetics of Indiana University, and is a tenured professor of Indiana University. He served as the director of the State Key Laboratory of Nutrition, Metabolism and Food Safety of Chinese Academy of Sciences, the vice president of Shanghai Institute of Chinese Academy of Sciences. He engaged in the basic research in the field of tumor, glucose and lipid metabolism for a long time. In recent years, he mainly focuses on the nutritional intervention of diabetes and other metabolic diseases. He is an outstanding young men winner of the State Foundation of China and enjoys the special government allowance of the State Council. He is selected as the national candidate of “New Century Millions Talent Project”, Academy of CAS. He is an excellent academic leader in Shanghai, won the “Meiji Dairy Science Award” and the “Tan Jiazhen Life Science Award”. He received lots of academic research funding such as the American Cancer Society Postdoctoral Fund, the American Endocrinology Association Fund and the American Heart Association Scientists Development Fund. He has been awarded the national Sino-American Biological co-cultured CUSBEA project, Published over 150 SCI academic papers, Posted in Nature, EMBO J, PNAS, Nat Communic, Mol Cell, Autophagy, Hepatology, Diabetes, Endocrinology, Cancer Research, Oncogene, and other journals. These papers were cited more than 4,000 times.
For better presentation, please browse vertically on the mobile end
